TScan Therapeutics

Historical price data

TScan Therapeutics is a fully integrated, clinical-stage biotech focused on unleashing the immune system through TCR-T cell therapies. Founded in 2018, the company's lead program, TSC-101, is in a Phase 1 trial for AML and MDS, and it has a pipeline of candidates for solid tumors and autoimmune disorders. TScan differentiates itself with a proprietary platform for target discovery and is advancing both ex vivo and in vivo engineered T cell approaches.

A proprietary target discovery platform that identifies how T cells recognize cancer and autoimmune targets, enabling the development of T cell receptor-engineered T cell (TCR-T) therapies for both ex vivo and in vivo applications.

2 drugs in pipeline

Total raised: $248M

TScan competes with established TCR-T players like Adaptimmune and Immunocore in solid tumors, and with other cell therapy companies in hematologic malignancies. Its differentiation lies in its proprietary discovery platform, which aims to systematically identify novel, high-quality targets to build a broad and potentially best-in-class pipeline.